HBM notches up another mega deal but is the model sustainable?
The biotech has agreed to sell rights to one of its cancer drugs under development for up to $670 million, adding more fuel to its share price rebound this year…
Medtide launches IPO to bulk up its weight-loss business
The pharmaceutical services firm wants to expand production of peptides used in anti-obesity drugs, but it faces fierce competition and other business risks Key Takeaways: The global market for developing…
Alphamab stake sale could signal harder times ahead
The founder of the cancer drug developer has cashed out part of his holdings after the stock hit a price peak, raising questions about the firm’s earnings outlook Key Takeaways:…
CSPC Pharma teases big bucks deals after earnings miss
The Chinese drug giant revealed it was in talks with three parties to license its products for up to $5 billion in potential fees, a day after it delivered lackluster…
Sinotau aims to become Hong Kong’s ‘first nuclear-medicine stock’
The company is China’s first to obtain approval for its innovative radiopharmaceuticals Key Takeaways: Sinotau has filed to list in Hong Kong, offering up two commercialized products and a net…
3SBio hits the big time with $6 billion cancer drug deal
The pharma giant Pfizer has bought international rights to the experimental cancer therapy and will take a $100 million equity stake in the Chinese drug developer Key Takeaways: The mega…
BRIEF: Hengrui Pharma surges in trading debut for $1.25 billion IPO
Shares of Jiangsu Hengrui Pharmaceuticals Co. Ltd. (1276.HK; 600276.SH) jumped in their Hong Kong trading debut on Friday, as the leading drug maker’s new IPO complemented its existing listing in…
